Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genomic analysis of Zhou8425B, a key founder parent, reveals its genetic contributions to elite agronomic traits in wheat breeding.

Plant communications·2024
Same author

Mapping and validation of a new QTL for adult-plant resistance to powdery mildew in Chinese elite bread wheat line Zhou8425B.

TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik·2018
Same author

[Chinese emergency medicine expert consensus on diagnosis and treatment of sepsis complicated with disseminated intravascular coagulation].

Zhonghua wei zhong bing ji jiu yi xue·2017
Same author

[Advances in biomarkers of ARDS].

Zhonghua wei zhong bing ji jiu yi xue·2017
Same author

Spatial and temporal variations of heavy metals in marine sediments from Liaodong Bay, Bohai Sea in China.

Marine pollution bulletin·2017
Same author

Exiguobacterium sp. A1b/GX59 isolated from a patient with community-acquired pneumonia and bacteremia: genomic characterization and literature review.

BMC infectious diseases·2017

Related Experiment Video

Updated: Jun 17, 2026

Combination Radiotherapy in an Orthotopic Mouse Brain Tumor Model
08:02

Combination Radiotherapy in an Orthotopic Mouse Brain Tumor Model

Published on: March 6, 2012

Personalized combination therapy for diffuse midline glioma: A case report.

Mengqi Sun1, Jizhou Zheng1, Long Gong1

  • 1Department of Radiation Oncology, Shenzhen People's Hospital (The Second Clinical Medical College of Jinan University, The First Affiliated Hospital of Southern University of Science and Technology), Shenzhen, Guangdong 518000, P.R. China.

Oncology Letters
|March 28, 2025
PubMed
Summary

Personalized combination therapy shows promise for H3K27M mutant diffuse midline glioma (DMG). This approach, combining surgery, radiation, chemotherapy, and novel therapies, achieved 28 months of survival in one patient, offering hope for improved outcomes.

Keywords:
H3K27M mutationcomprehensive treatmentdiffuse midline gliomalong-term survival

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

Related Experiment Videos

Last Updated: Jun 17, 2026

Combination Radiotherapy in an Orthotopic Mouse Brain Tumor Model
08:02

Combination Radiotherapy in an Orthotopic Mouse Brain Tumor Model

Published on: March 6, 2012

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

Area of Science:

  • Neuro-oncology
  • Genomic Medicine
  • Clinical Therapeutics

Background:

  • Diffuse midline glioma (DMG) is an aggressive brain tumor, often characterized by the H3K27M mutation.
  • Current treatment options for DMG are limited, with poor prognoses.
  • H3K27M mutation is a key driver in the pathogenesis of DMG.

Observation:

  • A case study of a 20-year-old female patient with H3K27M mutant DMG.
  • The patient received a multimodal treatment regimen including surgery, radiotherapy, chemotherapy, electric field therapy, immunotherapy, and targeted therapy.
  • The personalized combination therapy aimed to address the specific molecular and clinical characteristics of the patient's tumor.

Findings:

  • The patient achieved an overall survival of 28 months.
  • This survival duration suggests potential efficacy of the integrated therapeutic approach.
  • The combination therapy was tailored to the individual patient's condition and tumor profile.

Implications:

  • Personalized treatment strategies may offer improved survival benefits for DMG patients.
  • This case highlights the potential of combining conventional and novel therapies for rare and aggressive brain tumors.
  • Further clinical research is warranted to validate the efficacy of personalized combination therapy in larger cohorts of DMG patients.